Likewise, PT2385 was also validated in multiple in vivo models, showing dramatic tumor responses in animal models and consistent dose-dependent inhibition of HIF2A targets, while no effect was observed in genes that are targets of HIF1A [20]. Here, EPAS1 is linked to neoplasm.